tbuckley/cabot-search huggingface dataset:
APC fusions analysis in Chinese non-small cell lung cancer (NSCLC) using comprehensive NGS panel: A multicenter study.
Authors: Liping Wang, Chunwei Xu, Wen xian Wang, You-cai Zhu, Wu Zhuang, Yun-jian Huang, Yong Fang, Hong Wang, Yinbin Zhang, Yafei Wang, Meifang Chen, Jinluan Li, Shangli Cai, Meiyu Fang, Gang Chen, Tangfeng Lv, Yong Song
Journal: Journal of Clinical Oncology (2020)

e21086 Background: Currently, with the advances in detection techniques, such as next generation sequencing (NGS), more and more rare or atypical APC fusions had been identified. Such as APC-MCC, the importance of Wnt signaling in the pathogenesis of lung cancer and the efficacy of EGFR-TKI treatment had been demonstrated. Methods: A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2018. To determine the frequency of the APC fusions in NSCLC and other tumors, we analyzed data from 2743 clinical NSCLC cases, each of which had results from next-generation sequencing (NGS)-based 381 genes panel assay, analogous to the index patient. Results: Of this entire cohort, just two (0.07%) patients were identified with a APC fusion, including APC-MCC (1), APC-MRPL13 (1). The genes most frequently co-altered in patients with APC fusions were TP53 (100.00%), CCND1 (50.00%), ESR1 (50.00%), TNN (50.00%), MAP2K2 (50.00%) and POM121L12 (50.00%). Overall TMB in the APC fusions was low (median 2.16 mut/Mb). For treatments, both patients chose chemotherapy based on pemetrexed for first line, and a case example of advanced APC fusion NSCLC patients responding to anlotinib was actively being sought thru our database. Conclusions: The frequency of APC fusions in Chinese populations with NSCLC is extremely rare (0.08%). NGS can identify novel fusions and increase the list of actionable variants for patients. More patients can benefit from targeted treatment. In addition, for short-or long-term responses to TKI treatment, we can use the NGS assay to explore differential gene expression in the future.
Effect of combined enteral and parenteral nutrition on nutritional and immune status of patients after proximal gastrectomy
Authors: Jie Zhang, Jun-ben Wu, Shu-jing Wang, Tong-jun Zhang, Ben-gang Gong
Journal: BMJ (2011)

Parenteral nutrition (PN) was given to 40 patients with upper gastric carcinoma after proximal gastrectomies; and full enteral nutrition (EN) was subsequently given when bowels function recovered.The nutritional indicators including serum albumin ( Alb),prealbumin .(PA) and transferring,and immunological indicators including IgA,IgG,IgM,C3,C4 were measured before and 1st,8th day after operation.The data were processed by software SPSS 13.0.The average length of hospital stay was 14 d and the aerofluxus time was (58 ±6)hours.There were no changes in blood biochemistry,hepatic function and renal function pre- and post-operation( P ＞0.05 ).The nutritional and immune indicators except the IgM in 1 st day after operation were decreased significantly ( P ＜ 0.05 ).The immune indicators except the IgG in 8th day after operation were significantly improved in comparison of those before and 1st day after operation ( P ＜ 0.05 ).Post-operative complications occurred in 3 patients including 1 case of subphrenic infection and 2 cases of anastomotic leakage.After proper treatment,all patients recovered well.Combined application of EN and PN may improve nutrition and immune status of patients after proximal gastrectomy.

Key words: 
Gastrectomy; Enteral nutrition
Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.
Authors: Andrea S. Fung, Maryam Karimi, Stefan Michiels, Lesley Seymour, Elisabeth Brambilla, Thierry Le Chevalier, Jean-Charles Soria, Robert Arthur Kratzke, Stephen L. Graziano, Siddhartha Devarakonda, Ramaswamy Govindan, Ming-Sound Tsao, Frances A. Shepherd
Journal: Journal of Clinical Oncology (2020)

e21080 Background: The prognostic and predictive role of KRAS mutations and gene copy number aberrations (CNA) in early stage NSCLC is unclear. In this study, we characterize the prognostic effect of KRAS mutation status and concomitant CN gain in early stage NSCLC, and determine the ability to predict survival benefit from adjuvant chemotherapy. We hypothesize that concomitant KRAS mutations and CN gain will be prognostic of worse survival compared to KRAS mutations alone. Methods: Clinical and genomic data from The LACE (Lung Adjuvant Cisplatin Evaluation)-BIO consortium was utilized. CNA were categorized as Gain or Neutral (Neut)/Loss; mutation status was defined as wild type (WT) or mutant (MUT). WT+Neut/Loss (reference), WT+Gain, MUT+Gain and MUT+Neut/Loss groups were compared in all patients and the adenocarcinoma subgroup. Primary endpoint was lung-cancer-specific survival (LCSS); secondary endpoints were DFS and OS. Survival curves were assessed using Kaplan-Meier and log-rank tests. Concomitant KRAS CNA and mutation status was correlated to endpoints using a Cox proportional hazards model stratified by trial and adjusted for treatment, age, gender, histology, WHO performance status, surgery type, tumor and nodal stage. A treatment-by-variable interaction was added to evaluate predictive effect. Results: 946 (399 adenocarcinoma) patients had complete KRAS mutation, CNA and clinical data: 41 (30) MUT+Gain, 145 (99) MUT+Neut/Loss, 125 (16) WT+Gain, 635 (254) WT+Neut/Loss. There was a negative prognostic effect of KRAS MUT+Neut/Loss for LCSS (HR = 1.32 [1.01-1.71]) on univariable analysis, and to a lesser extent after adjusting for covariates (HR = 1.28 [0.97-1.68]). A similar non-significant trend was observed in KRAS MUT+Gain patients for LCSS (HR = 1.34 [0.83-2.17]), DFS (HR = 1.34 [0.86-2.09]) and OS (HR = 1.59 [0.99-2.54]). There was no significant predictive effect in the overall population; however, a potential predictive effect of KRAS for OS was seen in the adenocarcinoma subgroup (interaction p = 0.046). KRAS MUT+Gain was associated with a beneficial effect of chemotherapy on DFS (HR = 0.33 [0.11-0.99], p = 0.048), with a non-significant trend also seen for LCSS (HR = 0.41 [0.13-1.33]) and OS (HR = 0.40 [0.13-1.26]). Conclusions: A small prognostic effect of KRAS mutation was identified for LCSS. A potential predictive effect of concomitant KRAS mutation status and CNA was observed for DFS in adenocarcinoma patients. These results could be driven by the small number of patients and require further validation.
Contrast-enhanced CT vs. X-ray examination in pest-operative breast cancer
Authors: Ni-ni Xu, Jiang-ping Zhou, Hai Zhou
Journal: BMJ (2009)

Imaging examination results of 50 breast cancer patients undergoing surgical treatment between January 2006 and December 2007 were retrospectively analyzed. Our data showed that 32 patients (64%) had positive results in contrast-enhanced CT, and metastases to lung, mediastinal lymph node, axillary lymph node, or chest wall were found in 22 (44.0%), 11 (22.0%), 10 (20.0%), and 3 patients (6.0% ), respectively. Only 10 patients (20%) had abnormal image manifestation in X-ray, 8 of which showed metastases to lung. In summary, contrast-enhanced CT examinations may be more useful in the detection of metastases in post-operative follow up of breast cancer.

Key words: 
Breast neoplasms;  Neoplasm metastasis
Progesterone treatment for early miscarriage
Authors: Wenhui Deng, Min Wang, Dan Zhou, Rui Sun, Fenghua Wei
Journal: BMJ (2017)

Spontaneous miscarriage is the most common complication of the first trimester, among which 90% are early miscarriage that occurs prior to the 12th week of the gestation. Low progesterone level may be the main cause of the early miscarriage. This article discusses the incidence, pathogenesis, progesterone treatment, and prediction marker of early miscarriage to provide clues for the clinical work.


Key words: 
Progestins; Abortion, missed
Pelvic abscess after ovulation in a patient with recurrent ovarian endometriotic cysts: case report and literature review
Authors: Ying Xu, Dandan Li, Guiyun Wang, Na Yin, Xin Zhang
Journal: BMJ (2019)

Retrospective analysis of 1 case admitted to our hospital and 15 domestic and foreign literature reports of endometriotic cyst infertility patients with pelvic abscess clinical data after ovulation. One patient in our hospital was treated with recurrent EMS-assisted assisted pregnancy. The endometriotic cyst rupture with pelvic abscess improved after surgery. At home and abroad, 15 cases of infertility were caused by ovarian endometriosis cysts, and 3 of them were recurrent. All the 15 cases showed lower abdominal pain, repeated body temperature, elevated white blood cells and erythrocyte sedimentation rate, and pelvic mass under ultrasound. 7 cases were treated with surgery and 8 cases were treated conservatively. The prognosis was good.


Key words: 
Endometriosis, ovary; Pelvic infection; Fertilization in vitro; Embryo transfer
Effects of lumbar sympathetic nerve modulation guided by computed tomography for treating female pelvic limb hyperhidrosis
Authors: Xiaomin Yang, Bing Huang, Ming Yao, Xuyan Zhou, Yaping Lu, Jianguo Guo
Journal: BMJ (2014)

A total of 17 cases with pelvic limb hyperhidrosis were selected for lumbar sympathetic nerve modulation. The puncture of lumbar sympathetic nerve was guided by computed tomography (CT) through the gap of L2-3 until the needle tip reached the lateral of the second or third lumbar vertebra body and outside of psoas major. A mixture of 1% lidocaine 3 ml and 30% Iohexol injection 0.3 ml was injected. If the diffusion of lidocaine was observed between lumbar vertebra body and psoas major. After 15 min, 5 ml of absolute alcohol was injected to modulate the lumbar sympathetic nerve. After 5 min, oximetry-derived perfusion index of toe and sole temperature increased (5.9±1.4) folds and (4.16±0.89)℃ on average respectively. Pelvic limb hyperhidrosis was all cured within 6 months and one case recurred after a year. There were no occurrences of complications. Lumbar sympathetic nerve modulation guided by CT may be used for treating female pelvic limbs hyperhidrosis.


Key words: 
Hyperhidrosis; Sympathectomy, chemical
Non-surgical Intestinal intubation plication for partial adhesive small-bowel obstruction
Authors: De-chun Li
Journal: BMJ (2008)

A 300 cm-long ileus tube was inserted from nasal cavity to the jejunum under the radiophotography guidance in 16 patients with recurrent adhesive small-bowel obstruction. Along with entire intestinal decompression, the ileus tube was moved forward to the terminal ileum and remained for 13 to 25 days for internal intubation plication. All the participants improved during the follow-up (range, 8 months to 2 years), and no intestinal adhesion or obstruction occurred. Non-surgical intestinal intubation plication might be a simple, safe and effective treatment for adhesive intestinal obstruction.

Key words: 
Intestinal obstruction; Catheterization
Camrelizumab in the treatment of patients with advanced lung cancer: A multicenter, prospective, cohort study.
Authors: Rong Wang, Mei Ji, Meiqi Shi, Dong Hua, Lianke Liu, Kaihua Lu, Hua Shen, Meng Chen, Wei Cai, Bi Chen, Chao Gao, Changhua Yu, Yongqian Shu
Journal: Journal of Clinical Oncology (2020)

e21650 Background: Camrelizumab is a humanized PD-1 monoclonal antibody. The efficacy of camrelizumab monotherapy or combined with chemotherapy in the treatment of advanced NSCLC had been demonstrated with promising anti-tumor activity in previous studies. However, in the real-world clinical practice, the activity of camrelizumab in patients with advanced lung cancer is poorly characterised. We sought to analyse the antitumour activity and toxicity of camrelizumab in advanced lung cancer to explore benefit subgroups and optimal treatments. Methods: This is a multicentre, prospective cohort study of advanced lung cancer in Jiangsu province, China. Eligibility required patients with histologically confirmed advanced lung cancer who couldreceive treatment regimen based on camrelizumab. No other restrictive inclusion criteria were applied. Data were captured with electronic uniform database templates to ensure consistent data collection. Primary endpoint is progression-free survival (PFS), Secondary endpoints are adverse events (AE), objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Results: 97 pts with advanced lung cancer were enrolled from August 7, 2019 to December 20, 2019. Median age was 64, male 82.5%, adenocarcinoma 50.5%, squamous carcinoma 29.9%, SCLC 14.4%. 30.9% were treated as first-line therapy, 24.7% were second-line treatment, 44.4% were third-line and above treatment. Treatment regimens included camrelizumab monotherapy 13.4%, combination chemotherapy 52.6%, combination anti-angiogenic therapy 24.7%. 52 pts were accessable for efficacy analysis. 11 (21%), 37(71%), and 6(8%) patients showed partial response (PR), stable disease (SD), and progression disease (PD), respectively. The ORR, DCR was 21.2%, 92.3%. 72 pts had experienced the safety assessment. This was an early stage of data analysis, PFS has not yet reached. Major AE was reactive cutaneous capillary hyperplasia (RCCEP) (20/72), no Grade≥3 RCCEP occurred. Other common AEs were eutrophil count decreased (14/72), nausea (12/72), fatigue (11/72), white blood cell decreased (10/72). No treatment-related deaths occurred. Conclusions: This Real-world research showed current treatment status of advanced lung cancer and provides preliminary evidence for camrelizumab treating with advanced lung cancer, and we expect follow-up data to provide more clues. Clinical trial information: ChiCTR1900026089.
Epidemiological survey of high risk factors for cervical intraepithelial neoplasia in women
Authors: Shu-jun Cao, Jin-feng Qian, Ling Zhu
Journal: BMJ (2008)

One hundred and twenty-two patients with confirmed cervical intraepithelial neoplasia (CIN), as a result of occasional screening for uterine cervix cancer in our out-patient clinic between July 2006 and August 2007, and 122 control patients with cervicitis who received colposcopy during the same period were enrolled in this study. Our results showed that 72% participants didn't receive uterine cervix cancer screening during the past 2 years; 55% women had premarital sexual behavior. CIN was most commonly seen in 30 to 34 year old women. Occasional screening could identify 75% CIN. In comparison with the control group, the incidence of earlier first sexual behavior, marriage, and delivery, multiple pregnancy, and frequent abortion was significantly increased in the study group (P < 0.05). We suggest that increased access to uterine cervix cancer screening might be more important than technical improvement.

Key words: 
Cervical intraepithelial neoplasia;  Risk factors
Management of type 2 diabetes in China: the Happy Life Club, a pragmatic cluster randomized controlled trial using health coaches
Authors: Browning Colette, Chapman Anna, 杨辉, 刘硕, 张拓红, Enticott Joanne C, Thomas Shane A
Journal: BMJ (2016)

目的
与常规服务相比，评估健康教练使用动机谈话（MI）的干预对改善2型糖尿病（T2DM）患者的血糖控制，以及临床、心理社会和自我保健结果的影响。


设计
实用性群组随机对照试验。


研究地点
中国北京市丰台区社区卫生服务站（CHSs）。


参与者
在41家随机选取的CHSs（21家干预组和20家对照组），有21家干预组CHSs（372名患者）和18家对照组（296名患者）在开始时参与试验。


干预
干预组患者接受电话和面对面MI健康教练服务，并同时在CHSs接受常规的服务。对照组只接受常规的服务。2组的医疗费用均得到减免。


结局指标
在基线、6个月和12个月进行结果评估。主要指标是糖化血红蛋白（HbA1c）。次要指标包括一组人体测量学指标、血压、空腹血糖、社会心理和自我保健。


结果
在12个月时，没有发现HbA1c的治疗效果差别，[调整后差别为0.02, 95%可信区间（CI）-0.40~0.44,P=0.929]，干预组和对照组都显示出明显的改善。不过，2个次要指标：心理忧郁(调整后差别为-2.38,95%CI-4.64~-0.12, P=0.039)和收缩压(调整后差别为-3.57,95%CI-6.08~-1.05, P=0.005)显示为明显改善的结果，与明显的治疗效果差别相一致，并得到敏感性分析的支持。有意义的是，在HbA1c之外，两组均显示出甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇上的明显改善。


结论
在当今中国初级卫生保健改革的形势下，本研究是在中国第一个在CHSs实际现场开展的、特别针对T2DM的大规模群组随机对照研究。虽然没有在HbA1c上发现治疗效果差别，但在2组的很多结果（包括HbA1c）上呈现改善，该结果支持在中国对T2DM患者进行常规和免费的临床健康检查。


试验登记编号
ISRCTN01010526; 初步结果。
Inhibitory effect of PAI-I in perifocal and resection line tissues on tumor growth in women with melanoma.
Authors: Ludmila Ya. Rozenko, Elena M. Frantsiyants, Valeria A. Bandovkina, Natalia D. Cheryarina, Viktoria V. Pozdnyakova, Maria G. Ilchenko, Elena I. Agarkova, Natalia A. Maksimova, Oleg I. Kit, Yuriy V. Przhedetskiy
Journal: Journal of Clinical Oncology (2020)

e22083 Background: The ability of malignant tumors to invasion and metastasis is associated with increased activity of the plasmin/plasminogen family proteases. The purpose of the study was to analyze changes in the plasmin/plasminogen system in tumors and adjacent tissues in patients with cutaneous melanoma in dependence on their gender. Methods: The study included 13 men and 22 women with cutaneous melanoma pT 1-2 N 0 M 0 . Levels of plasmin (PAP), content and activity of uPA, content and activity of tPA, content and activity of PAI were determined by ELISA in homogenates of melanoma (M), perifocal (P) and resection line (RL) tissues after surgical treatment. All patients gave a voluntary informed consent for the study. Skin tissues obtained from 20 non-cancer patients after plastic surgery served as the control. Results: The maximal PAP content in women was found in M – 16.5 times higher than in control, in RL – twice higher; PAP in all tissues of men was on average 7 times higher than in control. The content and activity of uPA and tPA in M were elevated in patients of both genders: in women by more than 3 times, in men by 4.9 and 3.7 times for uPA, respectively, and on average by 1.4 times for tPA. Increased content and activity of PAI-I were observed only in M of women by 74.6 and 2.3 times respectively, while PAI-I levels in men were similar to control values, and its activity was 2.9 times higher. Content and activity of PAI in P and RL tissues of men did not exceed the norm despite an increased activity of uPA and tPA, while in women they were elevated on average by 4 and 1.8 times, respectively. Conclusions: A local increase in the content and activity of the PAI-I plasminogen activator inhibitor in P and RL tissues only in women is a distinctive gender characteristics that can inhibit the spread of melanoma.
Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
Authors: Christophe Le Tourneau, Valentin Calugaru, Edith Borcoman, Victor Moreno, Emiliano Calvo, Xavier Liem, Sebastien Salas, Bernard Doger, Olivier Choussy, Maria Lesnik, Xavier Mirabel, Nathalie Badois, Samar Krhili, Josefin Blomkvist, Nicolas Fakhry, Stéphanie Wong-Hee-Kam, Caroline Hoffmann
Journal: Journal of Clinical Oncology (2020)

6573 Background: The standard of care non-surgical approach for locally advanced head and neck squamous cell carcinoma (LA HNSCC) patients (pts) is concurrent chemoradiation with high dose cisplatin or cetuximab in case of contra-indication. Older age is a contra-indication to cisplatin, and cetuximab might not improve survival in older pts. It is therefore urgently needed to develop new treatment options for elderly pts with LA HNSCC. NBTXR3 are hafnium oxide nanoparticles that can enhance the efficacy of radiotherapy (RT) by increasing locally the deposited dose. In this phase I clinical trial we aimed to evaluate the feasibility and safety of NBTXR3 administered as intratumoral (IT) injection prior to RT in LA HNSCC elderly pts. Methods: Pts with stage III-IV LA HNSCC of the oropharynx or oral cavity ineligible for platinum-based chemoradiation received a single IT injection of NBTXR3 into a selected primary tumor and intensity modulated RT (IMRT; 70 Gy/35 fractions/7 weeks) [NCT01946867]. A 3+3 dose escalation design, tested NBTXR3 dose levels equivalent to 5, 10, 15, and 22% of baseline tumor volume, followed by a dose expansion at the Recommended Phase II Dose (RP2D). Primary endpoints included RP2D determination, and early dose limiting toxicities (DLT). NBTXR3 intratumoral bioavailability and anti-tumor activity (RECIST 1.1) were also evaluated. Results: Enrollment was completed at all dose escalation levels: 5% (3 pts), 10% (3 pts), 15% (5 pts), and 22% (8 pts). No early DLT or SAE related to NBTXR3 or injection were observed. The median follow-up from NBTXR3 administration is 7.6 months. One AE (Grade 1) related to NBTXR3 and four AEs (Grade 1-2) related to the injection were observed. RT-related toxicity was as expected with IMRT. CT-scan assessment showed a good dispersion of NBTXR3 throughout the injected tumor and not in surrounding healthy tissues. The RP2D was determined to be 22%. Preliminary efficacy was evaluated in pts who received the intended dose of NBTXR3 and RT. A complete response of the injected lesion was observed in 9/13 (69%) evaluable pts at doses ≥10% (2 unconfirmed) and an overall complete response in 5/13 (38%) evaluable pts at doses ≥10%. Preliminary safety and efficacy data of the dose expansion cohort at the RP2D will also be presented. Conclusions: NBTXR3 activated by RT was well tolerated at all tested doses and demonstrated promising preliminary anti-tumor activity. Recruitment is ongoing in the dose expansion cohort. These results demonstrate that further testing of NBTXR3 in this population is warranted. Clinical trial information: NCT01946867 .
农村社区居民代谢综合征患病情况及相关危险因素研究
Authors: 张建陶, 王亚龙, 张叶香, 陈聪, 沈洪兵
Journal: BMJ (2008)

国内外大量代谢综合征(MS)的流行病学研究显示,MS的发病存在较大的地区、种族和社会经济状况等差异,其发病受多种环境因素和遗传因素的影响[1].江苏省常州市武进区属经济发达地区,随着经济快速发展,人民生活水平显著提高,生活方式也发生显著变化。
Impact of detectable measurable residual disease on umbilical cord blood transplantation
Authors: Frédéric Baron, Myriam Labopin, Annalisa Ruggeri, Jorge Sierra, Stephen Robinson, Hélène Labussière‐Wallet, Michael Potter, Josep‐Maria Ribera, Eric Deconinck, Alessandro Rambaldi, Pierre‐Simon Rohrlich, Thierry de Revel, Eliane Gluckman, Arnon Nagler, Mohamad Mohty
Journal: American Journal of Hematology (2020)

The impact of measurable residual disease (MRD) on cord blood transplantation (CBT) outcomes has remained debated. To address this issue, we assessed the impact of measurable MRD at CBT on outcomes in large cohort of patients with acute leukemia. Inclusion criteria included adult patients with acute myeloid (AML) or acute lymphoblastic leukemia (ALL), CBT as first allo-HCT in first or second complete remission (CR) at transplantation, and known MRD status at the time of CBT. Data from 506 patients were included in the analysis. Among them, 317 patients had AML and 189 had ALL. Positive MRD was reported in 169 (33%) patients while the remaining 337 patients were MRD negative at CBT. At 2 years, relapse incidence was 18% in patients with MRD negativity vs 33% in those with MRD positivity at transplantation (P < .001). Two-year leukemia-free survival (LFS) and overall survival (OS) were 57% and 60%, respectively, in MRD negative patients, vs 38% (P < .001) and 48% (P = .004), respectively, in those with MRD positivity. There was no interaction between the impact of MRD on OS and LFS and diagnosis (ie, ALL vs AML), single or double CBT, and reduced-intensity or myeloablative conditioning. On multivariate analysis, MRD positivity was associated with a higher risk of relapse (HR = 1.8, P = .003), comparable non-relapse mortality (P = .44), worse LFS (HR = 1.4, P = .008) and a trend towards worse OS (HR = 1.3, P = .065). In conclusion, these data suggest that novel strategies that are aiming to achieve MRD negativity at CBT are needed for leukemic patients with positive MRD pre-CBT.